CHANDLER, Ariz. — (BUSINESS WIRE) — The Arizona Bioindustry Association (AZBio) today announced that Martha A. Brumfield, PhD, Special Advisor to the CEO and past President and CEO at the Critical Path Institute (C-Path) will be honored as the Jon W. McGarity Arizona Bioscience Leader of the Year at the 2019 AZBio Awards on October 2, 2019, at the Phoenix Convention Center.

“You probably know someone who is waiting for a cure. Most of us do.  It can take over 15 years and a billion dollars or more to bring a new life-saving or life-changing treatment to the people who are waiting for it,” shared AZBio President and CEO Joan Koerber-Walker. “Throughout her career, Dr. Brumfield has worked to bring new, safe, and effective treatments to market for patients who are waiting.”Continue reading→

Kalos Therapeutics is developing a platform of drugs containing multiple arrays of natriuretic peptide which have demonstrated a broad spectrum of anti-tumor activity with negligible or no known adverse effects. Continue reading→

WASHINGTON – Arizona Senator Kyrsten Sinema today led a bipartisan letter from members of the Arizona Congressional Delegation urging Congressional leaders to permanently repeal the medical device tax. Sinema was joined on the letter by Senator Martha McSally and Representatives Tom O’Halleran (AZ-01), Ann Kirkpatrick (AZ-02), Paul Gosar (AZ-04), Andy Biggs (AZ-05), David Schweikert (AZ-06), Debbie Lesko (AZ-08), and Greg Stanton (AZ-09).Continue reading→

Deep within the subterranean confines of Building C—the latest addition to the Biodesign Institute at Arizona State University—a pathbreaking machine is quietly taking shape. Designed to unlock some of nature’s tiniest and most fleeting mysteries, the Compact X-ray Free Electron Laser (CXFEL) is the only instrument of its kind in the world.

The device is the brainchild of physicist William Graves, a passionate authority on massive, intricate machines for leading-edge science. For the past 30 years he has worked on the design and construction of particle accelerators. The CXFEL represents ASU’s bold attempt to dramatically reduce the size of such instruments, making them suitable for universities and medical institutions.Continue reading→

Neonatal Abstinence Syndrome is the diagnosis given to infants that are withdrawing from opiates due to exposure prenatally. Neonatal withdrawal can take up to 8 weeks.  Hushabye Nursery provides a therapeutic and inviting environment of short-term medical care to infants suffering from Neonatal Abstinence Syndrome (NAS) and their families. They offer non-judgmental support, education and counseling to families in a cost-effective manner.  Continue reading→

The Flinn Foundation’s Bioscience Entrepreneurship Program has opened its 2020 application for Arizona early-stage bioscience firms seeking funding, professional support, and networking opportunities to grow their business.

The program provides $30,000 in non-dilutive funding support for up to six firms each year, administered through a nonprofit partner, and a professionally developed, yearlong plan specific to the needs of the individual firms.Continue reading→

CHANDLER, Ariz — (BUSINESS WIRE) — The Arizona Bioindustry Association (AZBio) today announced that Regenesis Biomedical, Inc.  has been named the Arizona Bioscience  Company of the Year and will be honored on October 2, 2019, at the AZBio Awards.

“Pain is real. If it is your pain, relief can be life changing,” stated Joan Koerber-Walker, president & CEO of AZBio.  “Regenesis Biomedical discovered an underutilized therapy and developed a unique platform that is delivering a solution to help patients manage their pain with a safe, easy to use, non-drug medical device.”Continue reading→

A $37.5 million grant from the National Institutes of Health will allow the University of Arizona to test a unique treatment for Alzheimer’s disease.
Continue reading→